300 related articles for article (PubMed ID: 21619887)
1. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
[TBL] [Abstract][Full Text] [Related]
2. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.
Verhoest PR; Fonseca KR; Hou X; Proulx-Lafrance C; Corman M; Helal CJ; Claffey MM; Tuttle JB; Coffman KJ; Liu S; Nelson F; Kleiman RJ; Menniti FS; Schmidt CJ; Vanase-Frawley M; Liras S
J Med Chem; 2012 Nov; 55(21):9045-54. PubMed ID: 22780914
[TBL] [Abstract][Full Text] [Related]
3. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task.
Vardigan JD; Converso A; Hutson PH; Uslaner JM
J Neurogenet; 2011 Dec; 25(4):120-6. PubMed ID: 22070409
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line.
Wunder F; Tersteegen A; Rebmann A; Erb C; Fahrig T; Hendrix M
Mol Pharmacol; 2005 Dec; 68(6):1775-81. PubMed ID: 16150925
[TBL] [Abstract][Full Text] [Related]
5. The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.
Rosenbrock H; Giovannini R; Schänzle G; Koros E; Runge F; Fuchs H; Marti A; Reymann KG; Schröder UH; Fedele E; Dorner-Ciossek C
J Pharmacol Exp Ther; 2019 Dec; 371(3):633-641. PubMed ID: 31578258
[No Abstract] [Full Text] [Related]
6. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.
van der Staay FJ; Rutten K; Bärfacker L; Devry J; Erb C; Heckroth H; Karthaus D; Tersteegen A; van Kampen M; Blokland A; Prickaerts J; Reymann KG; Schröder UH; Hendrix M
Neuropharmacology; 2008 Oct; 55(5):908-18. PubMed ID: 18674549
[TBL] [Abstract][Full Text] [Related]
7. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.
Kroker KS; Mathis C; Marti A; Cassel JC; Rosenbrock H; Dorner-Ciossek C
Neurobiol Aging; 2014 Sep; 35(9):2072-8. PubMed ID: 24746365
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP.
Kroker KS; Rast G; Giovannini R; Marti A; Dorner-Ciossek C; Rosenbrock H
Neuropharmacology; 2012 Apr; 62(5-6):1964-74. PubMed ID: 22245562
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
[TBL] [Abstract][Full Text] [Related]
10. Role of PDE9 in Cognition.
Dorner-Ciossek C; Kroker KS; Rosenbrock H
Adv Neurobiol; 2017; 17():231-254. PubMed ID: 28956335
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.
Boess FG; Hendrix M; van der Staay FJ; Erb C; Schreiber R; van Staveren W; de Vente J; Prickaerts J; Blokland A; Koenig G
Neuropharmacology; 2004 Dec; 47(7):1081-92. PubMed ID: 15555642
[TBL] [Abstract][Full Text] [Related]
12. The effect of phosphodiesterase inhibitors on the extinction of cocaine-induced conditioned place preference in mice.
Liddie S; Anderson KL; Paz A; Itzhak Y
J Psychopharmacol; 2012 Oct; 26(10):1375-82. PubMed ID: 22596207
[TBL] [Abstract][Full Text] [Related]
13. The Phosphodiesterase 9 Inhibitor PF-04449613 Promotes Dendritic Spine Formation and Performance Improvement after Motor Learning.
Lai B; Li M; Hu W; Li W; Gan WB
Dev Neurobiol; 2018 Sep; 78(9):859-872. PubMed ID: 30022611
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
15. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
16. Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor.
Nagy D; Tingley FD; Stoiljkovic M; Hajós M
Exp Neurol; 2015 Jan; 263():122-31. PubMed ID: 25315303
[TBL] [Abstract][Full Text] [Related]
17. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
[TBL] [Abstract][Full Text] [Related]
19. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models.
Hirst WD; Stean TO; Rogers DC; Sunter D; Pugh P; Moss SF; Bromidge SM; Riley G; Smith DR; Bartlett S; Heidbreder CA; Atkins AR; Lacroix LP; Dawson LA; Foley AG; Regan CM; Upton N
Eur J Pharmacol; 2006 Dec; 553(1-3):109-19. PubMed ID: 17069795
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus.
Uslaner JM; Parmentier-Batteur S; Flick RB; Surles NO; Lam JS; McNaughton CH; Jacobson MA; Hutson PH
Neuropharmacology; 2009; 57(5-6):531-8. PubMed ID: 19627999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
